April 21, 2020 Acad, Gov/Utilities Bio/Pharma/CRO Microscopy PAI Top-10 PR/Corporate

Roche receives FDA approval for cobas HPV test for use on the cobas 6800/8800 Systems to identify women at risk for cervical cancer

More than 99 percent of cervical cancers are caused by persistent high-risk HPV infection1 Cervical cancer is nearly 100 percent preventable with proper HPV vaccination, screening and treatment; expanding access helps reach more women2,3 cobas 6800/8800 Systems deliver full automation, helping laboratories meet the throughput and efficiencies that high-volume, HPV DNA screening programs require              Basel,... Read more

April 20, 2020 Acad, Gov/Utilities

US FDA and EMA accept applications for Roche’s OCREVUS (ocrelizumab) shorter 2-hour infusion time

Reduces infusion time to 2 hours from the current 3.5 hours for patients with relapsing or primary progressive multiple sclerosis, if approved Applications are based on data from the randomised, double-blind ENSEMBLE PLUS study, showing consistent safety to the currently approved OCREVUS dosing regimen              Basel, 20 April 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY)... Read more

April 17, 2020 Product Launch

Roche develops new serology test to detect COVID-19 antibodies

The new Elecsys Anti-SARS-CoV-2 serology test can support the detection of antibodies against SARS-CoV-2 in patients who have been exposed to the virus which causes COVID-19 The detection of these antibodies could help indicate if a person has gained immunity against the virus and inform treatment decisions Roche aims to have this test available by... Read more

April 7, 2020 Licensing, IP, and Legal

Roche provides regulatory update on risdiplam for the treatment of spinal muscular atrophy (SMA)

U.S. Food and Drug Administration (FDA) extends review time for risdiplam following agreed submission of additional data, including SUNFISH Part 2 Roche has submitted filing applications for risdiplam in seven countries with submission in China imminent Risdiplam is being investigated in infants, children and adults with Type 1, 2 or 3 SMA Basel, 07 April... Read more

March 24, 2020 Uncategorized

Roche response to COVID-19 pandemic

Roche response to COVID-19 pandemic Roche accelerates delivery and production of Actemra Roche is working around the clock to increase availability of COVID 19-tests Roche calls on governments across the world to work closely with industry to keep manufacturing and supply running Basel, 24 March 2020 – Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today... Read more

March 23, 2020 PAI Top-10

Roche announces Venclexta/Venclyxto combination improved overall survival in people with previously untreated acute myeloid leukaemia

Phase III VIALE-A study showed Venclexta/Venclyxto plus azacitidine helped people with the most common type of aggressive leukaemia in adults live longer compared to azacitidine alone Data will be shared with global health authorities and presented at an upcoming medical meeting  Basel, 23 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that... Read more

March 19, 2020 Bio/Pharma/CRO Clinical Research/Diagn. Microscopy

Roche initiates Phase III clinical trial of Actemra/RoActemra in hospitalised patients with severe COVID-19 pneumonia

Basel, 19 March 2020- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced  we are working with the Food & Drug Administration (FDA) to initiate a randomised, double-blind, placebo-controlled Phase III clinical trial in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), a part of the US Health and Human Services Office of the... Read more

March 17, 2020 Uncategorized

Roche Annual General Meeting 2020

Basel, 17 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). On the basis of COVID-19 Ordinance 2 of the Swiss Federal Council, no shareholders were admitted to attend the General Meeting in person. Roche... Read more

March 16, 2020 Licensing, IP, and Legal

Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance

The Roche Annual General Meeting 2020 will be held under conditions of the COVID-19 Ordinance 2 of the Federal Council To comply with regulatory requirements, voting at the AGM will be by independent proxy Shareholders who are physically present will be able to cast their votes through the proxy, but will not be admitted to... Read more

March 14, 2020 Uncategorized

Roche Annual General Meeting 2020 to take place under special conditions set by the authorities – electronic voting strongly recommended

Annual General Meeting on 17 March 2020 will take place as planned under conditions set by the authorities in Switzerland Roche strongly advises against physical participation and recommends electronic voting via the independent proxy Despite health measures participation will be at attendees’ own risk Basel, 14 March 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY)... Read more